Back to Results

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders. Its lead candidate, AD04, is a serotonin-3 antagonist being evaluated in Phase 3 clinical trials for alcohol use disorder. The company is also advancing additional drug candidates aimed at non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals was founded in 2010 and is headquartered in Glen Allen, Virginia. The company’s common stock is listed on the NASDAQ exchange under the symbol ADIL.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-ADIL
$4.20
0.1% Upside
Fair
$8.33
98.4% Upside
Bargain
Weak
0.0%
November 18, 2026
11.029 M
21.134 M
0.0%
69.4%
-7.0
19.3%
Valuation • Fair Value

Adial Pharmaceuticals Inc (NASDAQ-ADIL) Fair Value by Valuation Model

Review the available estimates for Adial Pharmaceuticals Inc (NASDAQ-ADIL), including Comps Fair Value.

Primary Valuation Read

Fair Value

$4.20

Estimated upside of 0.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$4.20

Comparable-company valuation reference.

Analyst Price Target

$8.33

Analysts imply upside of 98.4%.

How to read these valuation models

Use the 4 available valuation references for Adial Pharmaceuticals Inc (NASDAQ-ADIL) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Adial Pharmaceuticals Inc (NASDAQ-ADIL)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-11.491 M

Current operating profitability reference.

EBITDA Forecast

76 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Adial Pharmaceuticals Inc (NASDAQ-ADIL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Adial Pharmaceuticals Inc (NASDAQ-ADIL)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

2

Weak quality score that deserves closer review.

Altman Z-Score

-7.0

Lower score that deserves closer risk review.

FCF / Net Income

19.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Adial Pharmaceuticals Inc (NASDAQ-ADIL). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Adial Pharmaceuticals Inc (NASDAQ-ADIL)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 18, 2026

Days to Earnings

57

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Adial Pharmaceuticals Inc (NASDAQ-ADIL), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Adial Pharmaceuticals Inc (NASDAQ-ADIL) Stock Forecast & Technical Outlook

Review Adial Pharmaceuticals Inc (NASDAQ-ADIL) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Adial Pharmaceuticals Inc (NASDAQ-ADIL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Adial Pharmaceuticals Inc (NASDAQ-ADIL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Adial Pharmaceuticals Inc (NASDAQ-ADIL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Adial Pharmaceuticals Inc (NASDAQ-ADIL) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Adial Pharmaceuticals Inc (NASDAQ-ADIL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Adial Pharmaceuticals Inc (NASDAQ-ADIL)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Adial Pharmaceuticals Inc (NASDAQ-ADIL) has a Buy consensus, with 2 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 1
Sell 0
FAQ • Fast Investor Answers

Adial Pharmaceuticals Inc (NASDAQ-ADIL) Stock FAQ

Data-supported answers about Adial Pharmaceuticals Inc (NASDAQ-ADIL), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$4.20
Estimated upside 0.1%
Valuation Rating
Near Fair Value
Price is close to fair value
Analyst Target
$8.33
Implied upside 98.4%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Adial Pharmaceuticals Inc (NASDAQ-ADIL) is $4.20. This implies an estimated upside of 0.1% versus the current market price.

Based on the current fair value estimate, the stock is trading close to its estimated fair value.

The available analyst price target for Adial Pharmaceuticals Inc (NASDAQ-ADIL) is $8.33. The analyst target implies estimated upside of 98.4%.

The current financial health read for Adial Pharmaceuticals Inc (NASDAQ-ADIL) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Adial Pharmaceuticals Inc (NASDAQ-ADIL) is November 18, 2026.

The latest available data indicates no current dividend yield for Adial Pharmaceuticals Inc (NASDAQ-ADIL).

The current market capitalization listed for Adial Pharmaceuticals Inc is 11.029 M.

The current enterprise value listed for Adial Pharmaceuticals Inc is 21.134 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Adial Pharmaceuticals Inc is NASDAQ-ADIL, and the stock is listed on NASDAQ.

Adial Pharmaceuticals Inc (NASDAQ-ADIL) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Adial Pharmaceuticals Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Adial Pharmaceuticals Inc is 69.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B